Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
360 EUR | -0.83% | +2.13% | +0.14% |
May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play | |
Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |
Sales 2024 * | 1.38B 1.48B | Sales 2025 * | 1.48B 1.59B | Capitalization | 3.04B 3.27B |
---|---|---|---|---|---|
Net income 2024 * | 139M 150M | Net income 2025 * | 155M 167M | EV / Sales 2024 * | 2.26 x |
Net Debt 2024 * | 74.94M 80.66M | Net cash position 2025 * | 43.1M 46.39M | EV / Sales 2025 * | 2.02 x |
P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
19.8
x | Employees | 5,459 |
Yield 2024 * |
0.4% | Yield 2025 * |
0.45% | Free-Float | 48.53% |
Latest transcript on Virbac
1 week | +2.98% | ||
Current month | +1.40% | ||
1 month | +1.68% | ||
3 months | +6.14% | ||
6 months | +21.40% | ||
Current year | +0.97% |
Managers | Title | Age | Since |
---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Capron
BRD | Director/Board Member | 65 | 03-12-31 |
Chairman | 59 | 97-12-31 | |
Director/Board Member | 63 | 94-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.25% | 1 M€ | -.--% | ||
0.02% | 775 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 360 | -0.83% | 637 |
24-06-07 | 363 | -2.55% | 9,693 |
24-06-06 | 372.5 | +3.47% | 3,170 |
24-06-05 | 360 | +2.71% | 2,883 |
24-06-04 | 350.5 | -0.57% | 3,375 |
Real-time Euronext Paris, June 10, 2024 at 03:53 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.97% | 3.28B | |
-10.36% | 80.73B | |
+22.21% | 9B | |
+24.50% | 3.69B | |
+15.54% | 1.69B | |
-0.78% | 1.31B | |
-26.00% | 1.23B | |
-29.34% | 1.18B | |
-23.11% | 1B | |
+1.95% | 932M |
- Stock Market
- Equities
- VIRP Stock